Sepiapterin

Small molecule

Approvedregulatory verdict

Evidence outlook

Approved: Phenylketonuria

Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.

track record: Reliable signal

Also approved (2)
JP
  • Phenylketonuria (PKU), all ages and full spectrum of disease severity
Product first approved 2025finviz.com
EU
  • Treatment of hyperphenylalaninaemia (HPA) in adult and paediatric patients with phenylketonuria (PKU)
Product first approved 2025EMA
Featured evidence outside this drug's tracked markets:NCT03519711 · BH4 Deficiency · Phase 1/2 · completed · Weak signal

How the evidence outlook works ↗

All registered studies

Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase.

Phase 3 (3)
Phenylketonuria
NCT05166161 · PTC Therapeutics
2022-02-14 – 2026-07-21 · Phenylketonuria
What this study did
Phase 1/2 (1)
Other / comorbidity
NCT03519711 · PTC Therapeutics
2019-01-03 – 2020-10-02 · BH4 Deficiency, Hyperphenylalaninemia
What this study did

Competitive landscape

1 other tracked programme targets this mechanism, none of them ahead of this one.

This drug's own stage for Phenylketonuria: Approved. Competitors below are sorted furthest-along first.

DrugStageModalityMechanismEvidence signalReported efficacygraded featured trials
Sepiapterin: this drugApprovedSmall moleculePhenylalanine hydroxylase (PAH)Reliable signalNo reviewed efficacy summary in this indication
Pegvaliase (PALYNZIQ)ApprovedProtein / enzyme therapeuticPhenylalanine ammonia lyase (enzyme substitution)Weak signalFeatured results are safety only in this race
Sapropterin Dihydrochloride (Kuvan)ApprovedSmall moleculePhenylalanine hydroxylase (PAH)Reliable signal
NCT00104247: Change in Blood Phenylalanine Levels From Baseline to Week 6. (baseline to week 6): Sapropterin Dihydrochloride — Baseline Blood Phe Level: 843 micromole per liter (Standard Deviation 300); Week 6 Blood Phe Level: 607 micromole per liter (Standard Deviation 377); Mean Change in Blood Phe from Baseline to Week 6: -239 micromole per liter (Standard Deviation 38) | Placebo — Baseline Blood Phe Level: 888 micromole per liter (Standard Deviation 323); Week 6 Blood Phe Level: 891 micromole per liter (Standard Deviation 348); Mean Change in Blood Phe from Baseline to Week 6: 6 micromole per liter (Standard Deviation 36)
NCT00272792: Phenylalanine supplement tolerated at week 10: sapropterin 20.9 (SD 15.4) vs placebo 2.9 (SD 4.0) mg/kg/day; mean difference 17.7 (SE 4.5) mg/kg/day, P<.001 (n=33 and 12) (Trefz et al., J Pediatr 2009).
BEAM-304
—(overall)
Gene therapy / editingPAH gene (phenylalanine hydroxylase)not yet gradedNo reviewed efficacy summary in this indication

Upcoming events

(1 total)

Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Follow Sepiapterin to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.

Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2031 (1)
February 2031 (1)
Phase 3PhenylketonuriaRecruiting
Est. primary completion 2031-02-28 · NCT06302348 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

22 December 2025ApprovalSephience approved in Japan for PKU
JP, MHLW · Source ↗